BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AK129 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AK129\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06943820-2087@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AK129: Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:AK129\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: AK129 C
 ombination Therapy for Advanced Solid Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ak12
 9#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 943820
URL:https://assetmemo.bio/drug/ak129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642792-2087@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AK129: Phase 1/2 readout est. (NCT06642792)
DESCRIPTION:AK129\, phase 1/2.\nStudy: A Study of AK129 With or Without AK1
 17 in PD(L)1-refractory Classic Hodgkin Lymphoma\nEstimated primary comple
 tion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ak129#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06642792
URL:https://assetmemo.bio/drug/ak129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
